Interstitial cystitis (IC) is a chronic inflammatory condition of the bladder wall, characterized by pelvic pain, urinary urgency, and frequency. Its etiology is unknown. IC remains a diagnosis of exclusion. Although there are no uniformly effective therapies, many treatment options are currently available. We present an IC patient who successfully underwent LLLT using an 830 nm GaAlAs diode laser. After 40 LLLT treatment sessions, the interstitial symptom index total score which was previously 19 decreased to 8 and the interstitial problem index total score which was previous 15 decreased to 6. Symptoms of severe bladder irritation and pelvic pain, urinary urgency and frequency improved almost completely for an extended period.
Introduction
Interstitial cystitis (IC) is a debilitating urological disorder characterized by bladder pain and irritable voiding symptoms with an absent definable etiology. Classic and nonclassic types are recognized in IC. Classical IC is characterized by Hunner's ulcers and it affects approximately 5% to 10% of IC patients. Histologically Hunner's ulcers involve marked inflammation of the mucosa, submucosa and muscle layer with chronic inflammatory cells, including mast cells ulceration. The specific etiology of IC is unknown but it is widely multifactorial. Treatment includes conservative measures, such as oral or intravesical medication, dietary changes and bladder retraining. The therapeutic response to such modalities in patients with Hunner's ulcers is often brief and relapse is common. Other treatments include bladder distention and Nd:YAG laser treatment. Patients with severe and refractory disease may require cystectomy with urinary diversion. We present a rare case report of an IC patient who had good improvement after LLLT.
Case Report
The patient was a 58-year-old male with pelvic pain, urinary urgency, and frequency. In May, 2001, the patient was diagnosed as having early stage prostate hypertrophy with urinary frequency, and was prescribed tamsulosin hydrochloride and cernitis pollen extract. In July, 2002, the patient was admitted to the department of dermatology in a university hospital. Skin desquamation of the bilateral limbs was recognized, and he was treated with steroid ointment. The skin symptoms significantly improved. From autumn 2002, the pelvic pain became unremitting with urinary frequency of up to 60 times per day and night. In 2003, pelvic pain, urinary urgency, and frequency were recognized, the patient was admitted to a urological clinic, and was diagnosed as having acute prostatitis. After taking levofloxacin, varicella resembling multiple systemic erythema occurred, accompanied by more severe instances of the pelvic pain, urinary urgency, and frequency. After blister and ulcer formation on the periphery of the bilateral limbs, the patient who was diagnosed as having Stevens -Johnson syndrome (SJS) and the medication was stopped. (1, 2) The skin symptoms improved, but the pelvic pain, urinary urgency, and frequency still remained. At the Department of Urology, Kyorin University School of Medicine, further examinations were carried out to exclude other diseases associated with pelvic pain such as bacterial cystitis, bladder carcinoma, tuberculous cystitis and neurogenic bladder. Following bladder distention and a transurethral biopsy of the bladder mucosa the patient was finally diagnosed as having interstitial cystitis (IC) with glamorization. Pathologically neither malignancy nor any other abnormal findings were seen. After a second bladder distention and endoscopic laser surgery, the patient achieved 3 months spontaneous remission, following which he started taking suplatast tosilate, tamsulosin hydrochloride and an anti-inflammatory and analgesic drug.
In May 2006, the patient consulted a doctor in our clinic seeking improvement of his pelvic pain, urinary urgency, and frequency. He reported having ladder pain, scalding, urinary urgency at 5 minute intervals and insomnia. Routine blood and urinalysis results revealed nothing in particular, likewise CT and MRI imaging.
Treatment method
The IC patient was treated with an 830 nm continuous wave GaAlAs diode laser (OhLase-3D1, JMLL, Tokyo, Japan) according to the Proximal Priority Theory (PPT) once a week. (3) After attaching the OhLase-3D1 Neck-irradiator (JMLL), LLLT was performed on the neck, shoulders, marginal scapulae, lumbar region and, ankle joints with a stretching procedure, and also on the abdomen with pressure technique using the usual laser probe. Each treatment session lasted for 20 minutes with the following parameters: output power, 60 mW; irradiance (power density) 3 W/cm 2 ; and radiant flux (energy density) 60-80 J/cm 2 per point. Results
After only 5 sessions, the patient managed to sleep better for 2 hours during the night. After one treatment per week in the Treatment Methods section, urinary urgency and frequency improved from 5 minute intervals to 2 hourly intervals. After 2 months, all medications were stopped. After 20 sessions of LLLT, the patient's severe pain was relieved, and was able to play a round of golf. Dietary restrictions were stopped, and he was able to return to work as usual. The pain relief score (PRS) decreased to 1 after 30 LLLT sessions, and after 40 sessions the patient was able to urinate at will without any bladder pain. O'Leary & Sant's interstitial cystitis symptom index maximum score 20 points), which scores the degree of quality of life disturbance caused by interstitial cystitis, decreased from 19 to 8 points at 11 months after starting LLLT. Furthermore, interstitial cystitis problem Sasaki K. ET AL. Fig. 1 : The interstitial cystitis symptom and problem index scores at baseline scores before LLLT and After 40 LLLT sessions index (maximum score of 16 points) markedly improved from 15 to 6 points. (4) 
Discussion
The patient in the present study contracted got dysuria through prostate hypertrophy which was first discovered during a routine health checkup. Following administration of medication, the patient developed SJS. Pelvic pain and the burning on urination remained as post-treatment symptoms, even though the skin condition of the patient had improved. There is no combined disease of the nervous system such as cerebral infarction, spinal cord disease, and diabetes with the exception of acute cystitis, and the patient's symptoms failed to show any improvement despite administration of antibiotics. Hunner presented long term lower urinary tract symptoms 1915, reporting on a patient in whom an ulcer was discovered in the bladder. It was the first report of interstitial cystitis (IC). (5) Many clinical examinations and basic research studies on IC have been reported in Europe and America. Ovarist reported in Finland in 1975 on the morbidity rate of IC, with a standard diagnosis of edema, inflammatory cell infiltration, and fibrosis by bladder biopsy while ruling out chronic urinary tract infection and chronic dysuria. According to this report, the morbidity rates were 10.1 per 100,000 in the general population, and 18.1 per 100,000 in females (6) Jones reported in 1989 that there was a 0.5% possibility of contracting IC in the general population, based on the United States National Household Interview Survey. (7) On the other hand, Ito performed a questionnaire survey in Japan for 300 leading hospitals in 1998, and two IC patients were reported from 100,000 urology patients. , the criteria to be met include both a Hunner's ulcer and glomerulation and urinary urgency, and frequency. In our current case, following diagnosis by exclusion, the bladder was expanded and an uroscopic inspection was performed, which confirmed the presence of mucosal membrane cracks and glomerulation. In serious cases of IC, the cystitis is accompanied by particularly extreme pain. Although the actual etiology of IC is currently unknown, multifactorial elements are known to participate including increased permeability of the bladder mucosa, activation of mast cells, neurological factors, infection and so on. (9, 10, 11) IC is an inflammation of the entire bladder wall that differs from the usual cystitis, penetrates through the mucosa and reaches the muscle layer. IC is sometimes complicated with other diseases and symptoms including. SLE, Sjögren's syndrome, allergic rhinitis, the bronchial asthma and so on.
As for the diagnosis of IC, uroflowmetry, cystoscopic examination and biopsies are performed following after distension . of the bladder with water. A complete cure is difficult to obtain with conventional treatment, and substitutive therapy is chiefly performed. (12, 13, 14, 15) Typical substitutive therapy consists of pharmacotherapy such as mild tranquilizers such as tricyclic anti-depressant drugs, antihistamine, corticosteroids, Ca antagonists, pentosan polysulfate (PPS), and Nalmefen. As alternative treatment methods, several drugs including hyaluronic acid, heparin dimethyl sulfoxide (DMSO), bacillus Calmette-Guerin (BCG), Botulinum toxin A, resiniferatoxin (RTX), and PPS, are available for intravesical therapy for IC. These agents are also used for mucosal protection or as GAG-layer substitution. The nerve stimulation treatments with transcutaneous electrical nerve stimulation (TENS) and acupuncture have been reported in the treatment of IC. (16) On the other hand, cystoscopic excision of the ulcer, the bladder expansion, total cystectomy and urinary diversion are available surgical approaches, which are more invasive compared with other treatment methods. .Although the hydro-distension method is one of the popular approaches, recurrence is often noted in the short-term follow-up. (17, 18) IC remains an elusive condition to treat effectively. Current etiological concepts include neuromodulation therapy. In the presence of chronic inflammation of the bladder, previously silent afferent C fibers exhibit impulse transmission. LLLT has been proved to increase the blood circulation in the brain through action of the cervical spinal nerves and the descending inhibitory pathway. As a result, it is thought that pelvic pain, urinary urgency, and frequency were improved over the long term in our present patient because the promotion of blood circulation occurs systemically associated with LLLT-mediated restoration of parasympathetic dominance which possibly led to healing of the lesions in the bladder mucous membrane, and decreased inflammation in the muscle layer. (4) It is possible that hypersensitivity of the urinary bladder trigone, which influences the micturition desire, was controlled and LLLT stimulation was perhaps also able to control the extension receptor by raising the threshold in the spinal nerves. It is been recently suggested that the material discharged by extension of the bladder epithelium activates C-fibers through sensory nerve receptors, thus initiating urinary urgency. It is thought that nitrogen monoxide (NO) inhibits sensory nerves while the releasing factor members such as atropine (ATP), prostaglandin (PG) and acetylcholine (Ach) stimulate sensory nerves. There are two kinds of ATP, one being neuroATP released from cholinergic nerves, and the other being non-neuroATP released from the bladder epithelium. NeuroATP causes contraction of the smooth muscle of the bladder, and non-neuroATP stimulates sensation of the bladder through sensory nerves or the P2X3 receptor of the interstitial cells. It could be argued that LLLT controlled central nervous system feed-back and the peripheral sensory nerves, thus improving pelvic pain, urodynia, and urinary urgency. NeuroAch, which is similarly discharged from cholinergic nerves, causes the shrinkage of the bladder via the muscarinic smooth muscle receptors. In addition, non-neuroAch is released by extension of the bladder epithelium. (19) Additionally, because anticholinergic drugs can suppress hypersensitivity, LLLT was suggested as having an anticholinergic effect. Autoimmune diseases such as Sjögren's disease and allergic diseases such as atopic dermatitis or allergic rhinitis, have been well-reported as being improved with LLLT. LLLT was also presumed to be effective in this case though the exact mechanisms remain uncertain. (20) In this one patient, not only was significant improvement achieved in the interstitial cystitis symptom index and problem index, but also over 50% improvement in the pelvic pain, dysuria, and urinary agency were recognized. LLLT may thus be recognized as a novel approach in the treatment of IC, and further studies with larger patient populations are certainly merited as LLLT is painless, safe, easy to apply and well-tolerated by all patients.
